Corticosteroid-Induced Hyperglycemia: Monitoring Diabetic Patients on Steroids

Corticosteroids are one of the most predictable causes of hyperglycemia in diabetic patients, and one of the most frequently prescribed. Primary care physicians use them for asthma exacerbations, COPD flares, allergic reactions, joint injections, autoimmune conditions, and dermatologic disorders. Specialists prescribe them even more liberally. Every time a diabetic patient starts a steroid course, their glucose control is at risk.

The clinical challenge is not recognizing that steroids affect glucose (every clinician knows this). The challenge is monitoring appropriately during the steroid course, adjusting diabetes medications proactively rather than reactively, and documenting the clinical reasoning behind the intensified monitoring.

How Steroids Disrupt Glucose

Corticosteroids affect glucose through multiple mechanisms simultaneously, which is why their impact is so pronounced:

• Increased hepatic gluconeogenesis: the liver produces more glucose, particularly in the afternoon and evening
• Reduced peripheral insulin sensitivity: skeletal muscle and adipose tissue become less responsive to insulin
• Impaired pancreatic beta-cell compensation: in patients with existing diabetes, the beta cells cannot increase insulin output enough to overcome the added resistance
• Increased appetite and caloric intake: steroids stimulate hunger, leading to larger meals that compound postprandial glucose spikes

The glucose effect is dose-dependent, rapid (often within 4-8 hours of the first dose), and follows a characteristic pattern: afternoon and evening hyperglycemia that is significantly worse than morning fasting glucose.

Steroid Types and Their Relative Glucose Impact

Not all corticosteroids affect glucose equally. Duration of action, dose, and route of administration all matter.

Systemic Steroids (Highest Impact)

Medication	Relative Potency	Typical Use	Duration of Glucose Effect
Dexamethasone	Very high (25x hydrocortisone)	Severe inflammation, nausea, cerebral edema	36-54 hours per dose
Prednisone	Moderate (4x hydrocortisone)	Asthma, COPD, autoimmune conditions	12-36 hours per dose
Methylprednisolone	Moderate (5x hydrocortisone)	Dose packs, acute flares	12-36 hours per dose
Hydrocortisone	Baseline	Adrenal insufficiency, physiologic replacement	8-12 hours per dose

Prednisone is the most commonly encountered in primary care. A standard 5-day burst (40-60 mg/day tapering) will cause significant hyperglycemia in most diabetic patients, typically peaking on days 2-3.

Local and Inhaled Steroids (Lower but Not Zero Impact)

Intra-articular injections (triamcinolone, methylprednisolone) can cause systemic glucose elevation for 2-5 days after injection. A single knee injection of 40 mg triamcinolone has been shown to raise glucose by 30-50 mg/dL for 48-72 hours in diabetic patients. Patients and clinicians often do not anticipate this.

Inhaled corticosteroids (fluticasone, budesonide) at standard doses have minimal systemic glucose effect. At high doses (fluticasone > 500 mcg/day), modest glucose elevation is possible, particularly in patients with brittle diabetes.

Topical steroids applied to small areas have negligible systemic absorption. Extensive application of high-potency topicals (clobetasol over large body surface areas) can occasionally cause measurable glucose changes.

The Characteristic Glucose Pattern

Steroid-induced hyperglycemia follows a predictable daily pattern that differs from uncontrolled diabetes:

Morning fasting glucose: Often near baseline or modestly elevated. This is because most steroid doses are taken in the morning, and the glucose effect peaks 4-8 hours later.

Afternoon and evening glucose: Markedly elevated. Patients on morning prednisone will see their worst readings between 2 PM and 10 PM.

Overnight glucose: Begins to trend down as the steroid effect wanes, returning toward baseline by the following morning.

This pattern is important for monitoring because a fasting-only glucose check will underestimate the severity of steroid-induced hyperglycemia. Postprandial or late-afternoon readings are more revealing.

Monitoring During Steroid Courses

Short Courses (5-14 Days)

For diabetic patients starting a short steroid burst:

• Increase glucose monitoring frequency: at minimum, add a late-afternoon or pre-dinner check in addition to fasting glucose
• Check glucose daily for the duration of the course plus 48 hours after the last dose
• Set a threshold for intervention: if glucose consistently exceeds 250 mg/dL, contact the patient to discuss temporary medication adjustment
• Warn the patient in advance: “Your blood sugar will likely run higher than usual while you are on prednisone. This is expected. Check your glucose more often and call us if readings are consistently above 250.”

Chronic Steroid Use (Weeks to Months)

For patients on maintenance steroids (rheumatologic conditions, transplant immunosuppression, adrenal insufficiency):

• Establish a new baseline: the patient’s glucose targets and diabetes regimen need to account for the ongoing steroid effect
• Monitor A1C more frequently: quarterly A1C checks rather than the standard semi-annual
• Anticipate dose changes: when the steroid dose is tapered, diabetes medication adjustments are needed in the opposite direction to prevent hypoglycemia
• Document the steroid indication and dose alongside every glucose review; this context is critical for interpreting readings and justifying monitoring intensity

After Joint Injections

Patients often do not think of joint injections as “steroids” and may not report them. Proactively ask about recent injections when a patient’s glucose unexpectedly worsens.

• Monitor glucose for 3-5 days after any intra-articular steroid injection
• Warn patients in advance: “This injection contains a steroid that may raise your blood sugar for a few days. Monitor your glucose more closely until it returns to your normal range.”

Medication Adjustments During Steroid Courses

The specific diabetes medication adjustment depends on the patient’s current regimen and the steroid dose, but general principles apply:

Patients on oral agents only:

• Metformin can be continued but is unlikely to fully compensate for steroid-induced hyperglycemia at higher prednisone doses (> 20 mg/day)
• Sulfonylureas carry hypoglycemia risk when the steroid is discontinued; use with caution
• Temporary basal insulin may be the safest approach for patients with sustained glucose > 250 mg/dL

Patients on insulin:

• Increase basal insulin by 10-20% on the first day of steroids, with further adjustment based on readings
• Add or increase mealtime insulin for lunch and dinner to match the afternoon/evening glucose peak
• Reduce insulin back to baseline doses 24-48 hours after the last steroid dose to avoid hypoglycemia

Key documentation point: When adjusting diabetes medications in response to steroids, document that the adjustment is steroid-related and temporary. This prevents the next clinician from continuing the elevated dose after the steroid course ends.

Common Clinical Scenarios

Scenario 1: COPD Exacerbation Treated with Prednisone Burst

A diabetic patient on metformin and glipizide presents with a COPD exacerbation. The prescribing physician (PCP, urgent care, or ER) starts prednisone 40 mg daily for 5 days.

Monitoring approach:

• Check glucose 4 times daily (fasting, pre-lunch, pre-dinner, bedtime) for the duration of the steroid course
• Contact patient on day 2 to review readings
• If glucose is consistently > 250 mg/dL, consider temporary basal insulin
• Resume normal monitoring frequency 48 hours after the last prednisone dose

Scenario 2: Knee Injection for Osteoarthritis

A diabetic patient on insulin glargine receives a triamcinolone injection in the knee from their orthopedist.

Monitoring approach:

• Check glucose 3-4 times daily for 5 days post-injection
• Patient may need a 10-15% increase in basal insulin for 2-3 days
• Return to baseline insulin dose once glucose normalizes

Scenario 3: Chronic Prednisone for Rheumatoid Arthritis

A diabetic patient is maintained on prednisone 10 mg daily by their rheumatologist.

Monitoring approach:

• Establish new glucose targets that account for the ongoing steroid effect
• A1C every 3 months
• When the rheumatologist tapers the prednisone, proactively reduce diabetes medications to prevent hypoglycemia
• Coordinate with rheumatology on the taper schedule

Coordinating with Prescribing Specialists

The physician who prescribes the steroid is often not the physician managing the patient’s diabetes. This creates a coordination gap.

What to communicate to specialists:

• Ask prescribers to notify you when they start or change steroid doses for your diabetic patients
• Provide specialists with the patient’s current A1C and diabetes regimen so they can factor glucose risk into their prescribing decision
• For chronic steroid users, establish a shared understanding of who is adjusting diabetes medications when steroid doses change

What to request from the prescribing specialist:

• Notification of dose changes or planned tapers
• Expected duration of the steroid course
• Whether alternative non-steroidal treatments were considered

Practical Steps for Your Practice

1. Flag steroid prescriptions in your monitoring workflow. When a diabetic patient receives a new steroid prescription (from any provider), increase monitoring frequency immediately.
2. Educate patients proactively. Before the first dose, set expectations about glucose changes and provide a monitoring plan.
3. Document the temporal relationship. When glucose readings spike, note the steroid name, dose, start date, and expected duration. This creates a clear clinical narrative.
4. Adjust and communicate. Make temporary diabetes medication changes promptly and document them as steroid-related. Communicate with the prescribing specialist when appropriate.
5. Monitor the taper. Steroid discontinuation is as important to manage as initiation; the risk shifts from hyperglycemia to hypoglycemia if diabetes medications are not reduced accordingly.

Steroid-induced hyperglycemia is predictable, manageable, and well-documented. The practices that handle it well are the ones that monitor proactively and adjust quickly rather than discovering the glucose spike at the next quarterly A1C.